New multi-omics clues point to better pediatric TB diagnosis

Tuberculosis remains a persistent global threat for children: the study behind this report notes that more than a million children under 15 develop TB each year, and many never receive treatment because diagnosis is difficult. To tackle that diagnostic gap, researchers led by corresponding author Zaynab Mousavian carried out a multi-omics analysis focused on children with suspected disease. They collected plasma proteomics and metabolomics data from children with presumptive TB across four high-burden countries and combined those molecular layers to look for clearer signals of disease. Rather than relying on a single type of measurement, the team sought pathway-level clues and predictive biomarkers that might point to underlying biology and improve the accuracy of distinguishing true TB from other conditions. The approach is meant to both expand our understanding of what processes are active in pediatric TB and to identify measurable blood markers that could one day support faster, more reliable diagnosis for children who are currently hard to classify.

The team used pathway enrichment analysis with multiGSEA to detect immune and metabolic pathways associated with pediatric TB, and applied mixOmics and other multiview approaches for diagnostic biomarker discovery. Integration of the proteomics and metabolomics datasets revealed several pathways that were uniquely visible only when the data layers were combined. Notably, the analysis highlighted regulation pathways involving PTEN and RUNX2 and pointed to arginine and proline metabolism among metabolic changes tied to disease. For diagnostics, the researchers compared multi-omics signatures to those derived from single-omics data sets. They report that the integrated multi-omics model produced only a marginal improvement over single-omics models, while proteomics alone generally outperformed metabolomics and showed greater potential for accurately classifying Confirmed TB versus Unlikely TB in children.

These results illustrate the value of layering complementary molecular information to gain a deeper picture of disease biology and to hunt for workable biomarkers. The pathway-level findings — including PTEN, RUNX2 regulation and arginine and proline metabolism — give researchers specific biological leads to explore and may help explain how TB manifests differently in children. At the same time, the study signals that proteomics in plasma is a particularly promising avenue for improving diagnostic classification, even when a full multi-omics integration yields only modest extra benefit. For clinicians and test developers, this suggests prioritizing protein-based markers while continuing to explore combined approaches; for scientists, the pathway insights create focused hypotheses for follow-up studies. Altogether, the work led by Zaynab Mousavian demonstrates a practical route toward better understanding and potentially improving the diagnosis of pediatric TB using molecular data.